Skin & Hair

Cosmetic and dermatological peptides fall into several functional classes based on how they influence skin biology. Signal peptides (like Matrixyl, a palmitoyl pentapeptide) stimulate fibroblasts to produce more collagen, elastin, and other extracellular matrix components — essentially sending a "repair" signal that mimics the skin's natural wound-healing response. Neurotransmitter-inhibiting peptides (like Argireline and SNAP-8) work by a completely different mechanism: they interfere with the SNARE complex that controls neurotransmitter release at the neuromuscular junction, reducing the muscle contractions that cause expression lines. This is the same target as botulinum toxin (Botox), though peptides achieve a much milder, topical version of the effect. Copper peptides (GHK-Cu, AHK-Cu) deliver copper ions to the skin — copper is a cofactor for lysyl oxidase and other enzymes critical for collagen cross-linking and tissue remodeling — while the peptide component itself has independent signaling activity.

GHK-Cu is the most thoroughly researched peptide in this category. Beyond its role as a copper delivery vehicle, GHK-Cu has been shown to modulate the expression of over 4,000 human genes, with effects that include upregulating collagen synthesis, promoting angiogenesis, recruiting immune cells for tissue repair, and activating wound-healing pathways. It appears in multiple categories on this site because its effects extend far beyond cosmetic applications. AHK-Cu (Alanine-Histidine-Lysine copper) is a related tripeptide with research suggesting it may have stronger effects on hair follicle stimulation specifically. Matrixyl has some of the best clinical trial data in the cosmetic peptide space, with controlled studies demonstrating measurable improvements in wrinkle depth and skin thickness. Argireline (Acetyl Hexapeptide-3) and SNAP-8 (Acetyl Octapeptide-3) are the leading neurotransmitter-inhibiting peptides, with SNAP-8 being a longer-chain extension of Argireline designed for enhanced efficacy.

Melanotan II occupies a distinct niche in this category. It is a synthetic melanocortin receptor agonist that stimulates melanogenesis — the production of melanin in the skin — resulting in tanning without UV exposure. It was originally developed at the University of Arizona as a potential skin cancer prevention strategy. However, Melanotan II also activates multiple melanocortin receptors, producing side effects including appetite suppression, nausea, and sexual arousal (the latter leading to the development of PT-141). It remains unapproved and carries notable safety concerns including potential effects on existing moles and nevi.

Evidence standards vary dramatically within this category. Cosmetic peptides like Matrixyl and Argireline are typically evaluated through small manufacturer-sponsored trials measuring parameters like wrinkle depth with silicone replicas — a far lower bar than pharmaceutical clinical trials. GHK-Cu has a more robust academic research base spanning decades of published work. Melanotan II has been studied in clinical settings but remains unapproved due to safety concerns. When evaluating skin and hair peptides, it is particularly important to distinguish between marketing claims, in vitro data, and actual controlled clinical evidence.